These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16105131)

  • 1. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
    Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
    Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
    Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term results of interventional treatment of large unresectable hepatocellular carcinoma (HCC): significant survival benefit from combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) compared to TACE monotherapy].
    Lubienski A; Bitsch RG; Schemmer P; Grenacher L; Düx M; Kauffmann GW
    Rofo; 2004 Dec; 176(12):1794-802. PubMed ID: 15573291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
    Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
    Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
    Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
    Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Park KW; Park JW; Choi JI; Kim TH; Kim SH; Park HS; Lee WJ; Park SJ; Hong EK; Kim CM
    J Gastroenterol Hepatol; 2008 Mar; 23(3):467-73. PubMed ID: 17764529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
    Treiber G; Röcken C; Wex T; Malfertheiner P
    Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hepatocellular carcinoma with long acting somatostatin analogues.
    Samonakis DN; Moschandreas J; Arnaoutis T; Skordilis P; Leontidis C; Vafiades I; Kouroumalis E
    Oncol Rep; 2002; 9(4):903-7. PubMed ID: 12066229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
    Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
    Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response.
    Guglielmi A; Ruzzenente A; Pachera S; Valdegamberi A; Sandri M; D'Onofrio M; Iacono C
    Am J Gastroenterol; 2008 Mar; 103(3):597-604. PubMed ID: 17970836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of cirrhotic patients with early hepatocellular carcinoma treated by percutaneous ethanol injection or liver transplantation.
    Andriulli A; de Sio I; Solmi L; De Carlis L; Troisi R; Grasso A; Festa V; Caturelli E; Giacomoni A; Del Vecchio Blanco C; De Hemptinne B; Burroughs A; Perri F
    Liver Transpl; 2004 Nov; 10(11):1355-63. PubMed ID: 15497162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma.
    Okuwaki Y; Nakazawa T; Kokubu S; Hidaka H; Tanaka Y; Takada J; Watanabe M; Shibuya A; Minamino T; Saigenji K
    Am J Gastroenterol; 2009 Nov; 104(11):2747-53. PubMed ID: 19603009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts.
    Tesdal IK; Wikström M; Flechtenmacher C; Filser T; Dueber C
    Cardiovasc Intervent Radiol; 2006; 29(5):778-84. PubMed ID: 16779690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Minami Y; Ueshima K; Haji S
    Oncology; 2007; 72 Suppl 1():98-103. PubMed ID: 18087189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.